10x Genomics, Inc. Stock

Equities

TXG

US88025U1097

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
27.52 USD -0.22% Intraday chart for 10x Genomics, Inc. -5.62% -50.82%
Sales 2024 * 678M Sales 2025 * 790M Capitalization 3.28B
Net income 2024 * -188M Net income 2025 * -114M EV / Sales 2024 * 4.36 x
Net cash position 2024 * 324M Net cash position 2025 * 366M EV / Sales 2025 * 3.69 x
P/E ratio 2024 *
-17.4 x
P/E ratio 2025 *
-29.8 x
Employees 1,259
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.5%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.22%
1 week-5.62%
Current month-26.67%
1 month-24.17%
3 months-33.78%
6 months-31.91%
Current year-50.82%
More quotes
1 week
26.93
Extreme 26.93
29.45
1 month
26.75
Extreme 26.75
38.49
Current year
26.75
Extreme 26.75
55.96
1 year
26.75
Extreme 26.75
63.57
3 years
23.81
Extreme 23.81
208.99
5 years
23.81
Extreme 23.81
208.99
10 years
23.81
Extreme 23.81
208.99
More quotes
Managers TitleAgeSince
Founder 47 12-07-01
Founder 49 12-07-01
Director of Finance/CFO 49 18-09-30
Members of the board TitleAgeSince
Chairman 66 13-07-31
Director/Board Member 65 20-03-25
Director/Board Member 57 17-08-22
More insiders
Date Price Change Volume
24-04-24 27.52 -0.22% 1,589,340
24-04-23 27.58 -0.79% 1,991,587
24-04-22 27.8 -0.50% 1,792,088
24-04-19 27.94 -3.49% 2,078,467
24-04-18 28.95 -0.72% 2,956,118

Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT

More quotes
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
27.52 USD
Average target price
52.29 USD
Spread / Average Target
+90.00%
Consensus